Aclaris Therapeutics (ACRS) Change in Account Payables (2014 - 2026)

Aclaris Therapeutics' Change in Account Payables history runs 13 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 9.07% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 286.18% increase from a year earlier, with the FY2025 full-year figure at $8.4 million, up 301.7% from the prior year.
• Change in Account Payables slipped to $1.5 million in Q1 2026 per ACRS's latest filing, from $4.0 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $4.0 million in Q4 2025 and bottomed at -$3.5 million in Q2 2024.
• The 5-year median for Change in Account Payables is $393000.0 (2024), against an average of $274529.4.
• Across the five-year window, Change in Account Payables soared 233.79% in 2023 and plunged 654.31% in 2024, its largest moves.
• Year by year, Change in Account Payables stood at $2.7 million in 2022, then sank by 114.66% to -$394000.0 in 2023, then plunged by 654.31% to -$3.0 million in 2024, then jumped by 233.34% to $4.0 million in 2025, then tumbled by 61.82% to $1.5 million in 2026.
• Per Business Quant, the three latest ACRS Change in Account Payables figures stand at $1.5 million (Q1 2026), $4.0 million (Q4 2025), and $377000.0 (Q3 2025).